10/29/2025
New Drugs of 2025: Your Essential Practice Update is Here! 💊
The October issue of U.S. Pharmacist has published its annual New Drug Review 2025, providing in-depth profiles on the latest FDA-approved New Molecular Entities (NMEs) you need to know.
Our expert review by Jack DeRuiter, PhD and Hill Crest Professor, Pamela L. Holston,, RPh, BS, BA, and Adam Harnden, PharmD, BCPS, covers the clinical data, pharmacology, precautions, and dosing for game-changing therapies, including:
- Acoltremon (Tryptyr): A first-in-class treatment for Dry Eye Disease (DED), offering a new mechanism of action for millions of patients struggling with this common condition.
- Suzetrigine (Journavx): A novel, non-opioid oral analgesic approved for moderate-to-severe acute pain, providing an alternative to traditional pain management protocols.
- Gepotidacin (Blujepa): A first-in-class oral antibiotic for uncomplicated urinary tract infections (uUTIs), crucial for tackling the rise of drug-resistant bacteria.
- Vanzacaftor/Tezacaftor/Deutivacaftor (Alyftrek): A new triple combination therapy for Cystic Fibrosis (CF).
Staying current on NMEs is vital for patient counseling, drug utilization review, and medication safety.
Click below to read the full review and earn your Continuing Education (CE) credits:
[Link to: https://www.uspharmacist.com/article/new-drug-review-2025]
